

SAFETY DATA SHEET

Section 1: Identification		
Product Name	Spironolactone Oral Suspension, 25 mg/5 mL	
Recommended use	Treatment of heart failure and hypertension and management of edema	
Manufacturer	Annora Pharma Private Limited, Survey No. 261, Annaram Village, Gummadidala Mandal, Sangareddy, Telangana 502313, India (IND)	
Distributor	Camber Pharmaceuticals, Inc., Piscataway, NJ 08854	
Section 2: Hazard(s) Identification		
Health Hazards	May cause damage to organs through prolonged or repeated exposure. May damage fertility or the unborn child. May cause harm to breast-fed children	
Precautionary Statements	Do not handle until all safety precautions have been read and understood. Use personal protective equipment as required. Wash hands and face thoroughly after handling. Keep away from heat, sparks and open flames. Do not eat, drink, or smoke when using this product. Do not breathe dust/fume/gas/mist/vapors/spray	
Hazards not otherwise classified	None classified	
Section 3: Co	omposition/Information on Ingredients	
Active Ingredient	CAS	
Spironolactone	52-01-7	
Microcrystalline Cellulose & Carboxy methyl cellulose sodium	NA	
Glycerine	56-81-5	
Saccharin Sodium	128-44-9	
Simethicone Emulsion	8050-81-5	
Sorbic acid	110-44-1	
Potassium sorbate	24634-61-5	
Ammonium Glycyrrhizate	53956-04-0	
Malic Acid	6915-15-7	
Dibasic sodium phosphate anhydrous	7558-79-4	



Banana FL ART	NA	
Section 4: First-Aid Measures		
Eye Contact	Flush with copious amounts of water for at least 15 minutes. Hold eyelids away from eyeball to ensure thorough rinsing. Irrigate each eye continuously with normal saline during transport. Seek medical attention immediately	
Skin Contact	Wash the affected area with plenty of warm water and soap. If irritation, redness, or rash persists, seek medical attention	
Ingestion	Do not induce vomiting. Wash out mouth with copious amounts of water. Seek medical attention immediately	
Inhalation	Remove affected person to fresh air and keep patient at rest. Seek medical attention immediately	
Most Important Symptoms/Effects Acute or delayed	Repeated or prolonged exposure may cause hypercalcaemia, hyponatremia and other renal dysfunction.	
Notes to physicians or First Aid providers	This product should only be given to patients by medical professionals educated in the therapy intended for this product. Treat any symptoms and eliminate exposure.	
Sect	ion 5: Fire-Fighting Measures	
Suitable Extinguishing Media	Water spray, dry chemical, carbon dioxide, or foam as appropriate for surrounding fire and materials	
Unsuitable Extinguishing Media	None known	
Unusual Fire and Explosion Hazards	May form sulfur and/or carbon oxides under combustion	
Special Fire Fighting Procedures	Evacuate personnel to a safe area. Wear self-contained breathing apparatus and personal protective equipment to prevent contact with skin and eyes.	
Section 6: Accidental Release Measures		
Personal Precautions	Non-essential personnel should be evacuated from the affected area. Spills should be cleaned up in a manner that minimizes exposure to personnel. Personnel involved in the clean up of spills should wear the appropriate respiratory protection, gloves, eye protection, and protective coveralls. Minimize the generation of aerosols. Remove all sources of heat and ignition.	



Methods/Materials Used for containment & cleaning	Use an inert absorbent material to remove and collect spillage. Minimize the generation of aerosols. Dampen remaining residue with water, then clean spill area thoroughly with soap and water. Collect wash with absorbent material and transfer all waste to a labelled container for disposal. Observe all applicable regulations when disposing	
	of this substance	
Section 7: Handling and Storage		
Handling Precautions	Avoid all contact and inhalation of dust, mists, and/or vapors associated with the material. Clean equipment and work surfaces with suitable detergent or solvent after use. Wash hands and exposed skin thoroughly with soap and water after use. Remove any contaminated clothing and clean before reuse.	
Storage Precautions	Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Shake well before use. Dispense in a tight container as defined in the USP	
8. Expos	ure controls / personal protection	
Engineering controls	In a manufacturing setting, local exhaust ventilation may be necessary to control air contaminants. The use of local ventilation is recommended to control emissions near the source. Provide mechanical ventilation for confined spaces. If user operations generate aerosols, use ventilation to keep exposure to airborne contaminants below the exposure limit	
PERSONAL PROTECTIVE EQ	UIPMENT (PPE)	
Eye Protection	Wear appropriate chemical safety goggles, safety glasses, or face shield as described by OSHA's eye and face protection regulations in 29 CFR 1910.133. Have eyewash stations available where eye contact can occur	
Skin Protection	Avoid unintended skin contact. Wear gloves impervious to conditions of use. Additional protection may be necessary to prevent skin contact including the use of an apron, face shield, boots, or full body protection. A safety shower should be located in the work area.	



Respiratory Protection	If exposure limits are exceeded, approved respiratory protection should be worn. Seek professional assistance for proper selection of respiratory protection		
Section 9: Physical and Chemical Properties			
Physical State	Suspension		
Description	Spironolactone oral suspension 25 mg/5 mL is a white to off-white, banana flavored suspension. It is available in a		
	118 mL bottle NDC 31722-691-11		
	473 mL bottle NDC 31722-691-47		
Section 10: S	Stability and Reactivity		
Reactivity	No available data		
Chemical stability	Material is stable under normal conditions		
Possibility of Hazardous Reactions	Danger of dust explosion when handling solid drug substance		
Conditions to avoid	Intense heat		
Incompatible materials	Strong oxidizing agents		
Hazardous Decomposition Products	Under fire conditions, thermal decomposition may generate sulfur and/or carbon oxides		
Section 11: To	oxicological Information		
Ingestion	In an occupational setting, ingestion of this product is unlikely. Ingestion may cause irritation		
Inhalation	Although unlikely due to product form, inhalation of vapors may slightly irritate the nose, throat, and lungs. Symptoms are generally alleviated upon exposure to fresh air		
Skin contact	May be absorbed through the skin. Active ingredient has blood pressure lowering effects		
Eye contact	Avoid contact with eyes. May cause irritation of the eyes		
Signs and symptoms of overexposure	Possible gastrointestinal discomfort, dizziness, and/or headache		



Chronic effects	May include possible hypersensitivity, gastrointestinal discomfort, or effects on blood and blood forming organs	
Acute toxicity Values	LD 50 for active ingredient (oral, rat) = > 1 g/kg	
S	Section 12: Ecological Information	
Ecological Information	This product has not been tested for persistence,	
	biodegradability, bioconcentration, soil absorption, or	
	mobility. Care should be taken to avoid environmental release.	
Se	ection 13: Disposal Considerations	
Waste disposal method	It is the responsibility of the generator to determine at the time	
	of disposal whether the product meets the criteria of a	
	hazardous waste per regulations of the area in which the waste	
	is generated and/or disposed of. Waste disposal must be in	
	accordance with all local, state, and federal regulations. Wear	
	proper protective equipment when handling waste materials	
Waste disposal Containers	Waste materials must be placed in and shipped in appropriate	
	poly or metal waste pails or drums. Permeable cardboard	
	containers are not appropriate and should not be used. Ensure	
	that any required marking or labeling of the containers is done	
	in accordance with all applicable regulations	
S	Section 14: Transport Information	
U.S. DEPARTMENT OF TRANSI	PORTATION SHIPPING REGULATIONS:	
This product is not classified as hazardous under regulations of U.S. DOT 49 CFR 172.101		
Section 15: Regulatory Information		
U.S. FEDERAL REGULATIONS TOXIC SUBSTANCE CONTROL ACT (TSCA): All components of this product are included on the TSCA inventory		



Section 16: Other Information, including date of preparation or last revision

Issue Date: 13-12-2024

Version: 00

Further information: NA

Revision date: NA

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Hetero Labs Limited shall not be held liable for any damage resulting from handling or from contact with the above product. Hetero Labs Limited reserves the right to revise this SDS.